News

The therapy, a once-daily oral medicine, was initially approved in the US in May 2019 under the name Qternmet XR.

The organisation updates its MS Guideline to state that Sativex should be offered to treat spasticity in people with the disorder.

The study is the sixth Phase III trial of the drug’s programme.

Only one drug has been approved for the indication in the lat 60 years, GlaxoSmithKline’s Benlysta (belimumab), which was also the first-ever biologic treatment for the disease.

More than half of the public are not aware the condition may be preventable, and just under half are unaware of the steps that can be taken to prevent or delay the development of the condition.

The study was the first randomised trial to test the abdominal stitch in this group of women.

42.2% of non-radiographic axial spondyloarthritis patients showed a significant and clinically meaningful reduction in disease activity.

Gilead will now initiate two new clinical trials, for both treatment-naïve and multidrug resistant HIV-1.

The committee initially published a draft final appraisal for the drug in October, and just last week the SMC approved the treatment for use on NHS Scotland.

Patients had 50% fewer flares on the drug compared to placebo.

The money will go towards a potential new therapy and project, seeking to discover new ways that may prevent brain cell death.

24-week data from the clinical trial showed at least a 20% improvement in disease signs and symptoms compared to placebo.

The committee accepted breast cancer and kidney cancer treatments, but rejected one non-small cell lung cancer (NSCLC) therapy.